MARCH 2013 Summary of Changes to the Queensland Health List of Approved Medicines (LAM)
as recommended by the Queensland Health Medicines Advisory Committee (QHMAC)
ITEM
NUMBER
MEDICINE
COMMITTEE
DECISION
DATE
EFFECTIVE
13/018
ALCOHOL (ETHANOL)
INJECTION 100%, 5mL
ALPROSTADIL Injection
500 microgram per mL
ADDED
30-Apr-13
ADDED
30-Apr-13
Neonatal and Paediatric Staff Specialists to use to temporarily
maintain the patency of the ductus arteriosus until corrective or
palliative surgery can be performed in neonates who have congenital
heart defects and who depend upon a patent ductus for survival.
13/018A2
Digoxin immune Fab
(Ovine) Powder for
injection 40mg
(DigiFab®)
ADDED
30-Apr-13
Specialist Staff and Country Medical Superintendents for the
treatment of cardiac glycoside intoxication resulting in life-threatening
cardiac arrhythmias; cardiac arrest; cardiac decompensation with
hypotension; serum potassium >5.5mmol/L. In the absence of these
recognised indications of cardiac glycoside toxicity, use may be
based solely on serum digoxin concentration in either chronic toxicity
(if >8 micrograms/L ) or in acute overdose (if >16 micrograms/L).
13/012
ICATIBANT Injection,
single use pre-filled
syringe 30mg in 3mL
ADDED
30-Apr-13
Immunology physicians or Emergency Department physicians, after
consultation with an immunology physician, for the treatment of
patients with previously confirmed hereditary angioedema for:
a) Acute attacks of hereditary angioedema, including angioedema
affecting the upper respiratory tract and persistent abdominal attack
resulting in significant intestinal obstruction;
b) Use prior to surgery – significant dental and other surgery;
c) During pregnancy for control of attacks; and
d) For outpatient use as per the PBS indications.
13/011
RESTRICTION
ITEM
NUMBER
MEDICINE
COMMITTEE
DECISION
DATE
EFFECTIVE
RESTRICTION
13/004
INDOCYANINE GREEN
Injection, powder for
reconstitution
25mg in 5mL
ADDED
30-Apr-13
Surgical consultants, hepatologists and registrars for patients
undergoing pre-operative assessment for liver resection. Where an
item is not TGA approved, patients should be made fully aware of its
status and appropriate consent obtained.
13/018
OSELTAMIVIR
PHOSPHATE Powder
for oral suspension
6mg/mL, 65mL
ADDED
30-Apr-13
Specialist Staff and Country Medical Superintendents on the advice
of an Infectious Diseases Physician or a Clinical Microbiologist or in
accordance with an Infectious Diseases / Clinical Microbiology
approved protocol for:
a) Treatment of clinically suspected or laboratory proven influenza in
inpatients only (not for general use in Emergency Departments
unless admission is intended); and b) Prophylaxis of inpatients who
are close contacts of inpatients with laboratory proven influenza on
the advice of
an infectious diseases physician, clinical microbiologist or infection
control practitioner. Oseltamivir therapy should be ceased if influenza
polymerase chain reaction (PCR) test of a nasopharyngeal swab or
aspirate is negative.
OR In accord with a QH pandemic influenza protocol.
13/013
MYCOPHENOLATE
(SODIUM) Tablet
180mg, 360mg
AMENDED
30-Apr-13
Specialist Staff for use in accord with Highly Specialised Drugs
Program and PBS indications.
13/016
PREGABALIN
CAPSULE
25mg, 75mg, 150mg,
300mg
AMENDED
30-Apr-13
Specialist Staff and Country Medical Superintendents for use as per
the PBS indications for neuropathic pain
13/005
GABAPENTIN
CAPSULE
100mg, 300mg, 400mg
AMENDED
30-Apr-13
13/014A
RIVAROXABAN Tablet
10mg
AMENDED
30-Apr-13
Specialist Staff and Country Medical Superintendents for partial
epilepsy not controlled by other drugs; and continuation of existing
patients being treated for neuropathic pain. (Note: In early 2014,
gabapentin may no longer be LAM listed for neuropathic pain.)”
For orthopaedic prophylaxis of venous thromboembolism in total hip
and knee replacement.
Page 2 of 6
ITEM
NUMBER
MEDICINE
COMMITTEE
DECISION
DATE
EFFECTIVE
RESTRICTION
13/009
ROCURONIUM
BROMIDE Injection
50mg in 5mL
AMENDED
30-Apr-13
Emergency Specialists, Specialist Anaesthetists and Country Medical
Superintendents
13/006
SUGAMMADEX
SODIUM INJECTION
500mg in 5mL
AMENDED
30-Apr-13
For use by credentialed anaesthetists and Emergency Physicians for
emergency reversal of rocuronium in patients who cannot be
intubated or cannot be oxygenated. [Only limited stock may be held
outside pharmacy - on the difficult intubation trolley. All other use of
sugammadex must be on an individual patient approval basis, with
approval by the Director of Anaesthetics, the Director of Emergency
Medicine or nominated representative, and in line with the SWAPNET
guideline. (Available at
http://qheps.health.qld.gov.au/patientflow/docs/swapnet_sugam_guid
e.pdf)]
13/003
HYDROMORPHONE
HYDROCHLORIDE
Tablet, modified release
4mg,
8mg
IV 5HT3
ANTAGONISTS FOR
USE IN PONV
(ONDANSETRON
Injection 4mg in 2mL
and GRANISETRON
Injection 1mg in 1mL)
LOSARTAN Tablet
25mg,
50mg
DEFERRED
12/097
13/022
DEFERRED
DEFERRED
Page 3 of 6
ITEM
NUMBER
MEDICINE
COMMITTEE
DECISION
13/019
MAGNESIUM SULFATE
in Water for Injection
4g/20mL (20%) and
10g/50mL (20%) Prefilled syringes
DEFERRED
12/098
POSTOPERATIVE
NAUSEA AND
VOMITING (PONV)
Guidelines
SUCROSE Oral solution
24%, 1.5mL (Phebra)
TRANEXAMIC ACID
INJECTION 100mg/mL,
10mL
DEFERRED
13/018
ALCOHOL (ETHANOL)
INJ ABSOLUTE (5.5
Cal per mL) 20mL
DELETED
30-Apr-13
13/018
BETAMETHASONE
VALERATE CREAM
0.05%, 30g
DELETED
30-Apr-13
13/018
BETAMETHASONE
VALERATE OINTMENT
0.05%,
15g,
30g
CIMETIDINE
INJECTION
200mg in 2mL
Digoxin immune Fab
(Ovine) Powder for
injection 38mg
(Digibind®)
DELETED
30-Apr-13
DELETED
30-Apr-13
DELETED
30-Apr-13
13/021
12/094
13/018
13/018A1
DATE
EFFECTIVE
RESTRICTION
DEFERRED
DEFERRED
Page 4 of 6
ITEM
NUMBER
MEDICINE
COMMITTEE
DECISION
DATE
EFFECTIVE
13/018
DOCUSATE with
GLYCERIN and SOFT
SOAP Enema
disposable 5mL
DELETED
30-Apr-13
13/018
INDOMETHACIN EYE
DROPS 10mg per mL
(1%), 5mL
DELETED
30-Apr-13
13/018
NICOTINAMIDE
TABLET 250mg
OSELTAMIVIR
PHOSPHATE Powder
for oral suspension
12mg/mL, 75mL
DELETED
30-Apr-13
DELETED
30-Apr-13
13/018
PROCAINAMIDE
HYDROCHLORIDE
CAPSULE 250mg
DELETED
30-Apr-13
13/018
PROCAINE
HYDROCHLORIDE
INJECTION
40mg in 2mL (2%)
DELETED
30-Apr-13
13/018
STREPTOKINASE
INJECTION
1,500,000 units
SUGAMMADEX
SODIUM INJECTION
200mg in 2mL
DELETED
30-Apr-13
DELETED
30-Apr-13
13/020
OMEGA-3-ACID ethyl
esters 90, Capsule
1,000mg
NOT ADDED
13/008
BOTULINUM TOXIN
TYPEAInjection100units
NOT
AMENDED
13/018
13/006
RESTRICTION
Page 5 of 6
ITEM
NUMBER
MEDICINE
COMMITTEE
DECISION
13/014
FOR INFORMATION FINAL REPORT OF
THE REVIEW OF
ANTICOAGULATION
THERAPIES IN ATRIAL
FIBRILLATION
NOTED
DATE
EFFECTIVE
RESTRICTION
Page 6 of 6